A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

被引：0
|
作者：
Landen, Charles N.
Buckanovich, Ronald J.
Sill, Michael
Mannel, Robert S.
Walker, Joan L.
Disilvestro, Paul
Mathews, Cara Amanda
Mutch, David Gardner
Hernandez, Marcia
Martin, Lainie P.
Bishop, Erin
Gill, Sarah
Gordinier, Mary E.
Burger, Robert Allen
Aghajanian, Carol
Liu, Joyce F.
Moore, Kathleen N.
Bookman, Michael A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Gynecol Oncol Grp Stat & Data Ctr, Buffalo, NY USA
[4] Stephenson Canc Ctr, Oklahoma City, OK USA
[5] Univ Oklahoma Hlth Sci Ctr, Oklahoma City, OK USA
[6] Women Infants Hosp, Providence, RI USA
[7] Brown Univ, Women & Infants Hosp, Dept Obstet & Gynecol, Program Womens Oncol, Providence, RI USA
[8] Washington Univ St Louis, Sch Med, St Louis, MO USA
[9] Mercy Hosp Springfield, Springfield, MO USA
[10] Univ Pennsylvania, Abramson Canc Ctr, Philadelphia, PA USA
[11] Froedtert & Med Coll Wisconsin, Milwaukee, WI USA
[12] Nancy N & JC Lewis Canc & Res Pavil, Savannah, GA USA
[13] Louisville Oncol, Louisville, KY USA
[14] Univ Pennsylvania, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Dana Farber Canc Inst, Boston, MA USA
[17] Univ Oklahoma Hlth Sci Ctr, Div Obstet & Gynecol, Dept Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA
[18] Univ Arizona, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5501
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Sabbatini, Paul
    Dupont, Jakob
    Aghajanian, Carol
    Derosa, Felicia
    Poynor, Elizabeth
    Anderson, Sybil
    Hensley, Martee
    Livingston, Phillip
    Lasonos, Alexia
    Spriggs, David
    McGuire, William
    Reinartz, Silke
    Schneider, Sally
    Grande, Cathy
    Lele, Shashikant
    Rodabaugh, Kerry
    Kepner, James
    Ferrone, Soldano
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5503 - 5510
  • [2] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Reply
    Sabbatini, Paul
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 4026 - 4027
  • [3] Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
    Landen, Charles N.
    Buckanovich, Ronald J.
    Sill, Michael W.
    Mannel, Robert S.
    Walker, Joan L.
    Disilvestro, Paul A.
    Mathews, Cara A.
    Mutch, David G.
    Hernandez, Marcia L.
    Martin, Lainie P.
    Bishop, Erin
    Gill, Sarah E.
    Gordinier, Mary E.
    Burger, Robert A.
    Aghajanian, Carol
    Liu, Joyce F.
    Moore, Kathleen N.
    Bookman, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (21) : 2537 - 2545
  • [4] A phase II study of cetuximabpaclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer.
    Aghajanian, C
    Sabbatini, P
    Derosa, F
    Gerst, S
    Spriggs, DR
    Dupont, J
    Hensley, ML
    Pezzulli, S
    Konner, J
    Schilder, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 466S - 466S
  • [5] Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Hagemann, Andrea R.
    Novetsky, Akiva P.
    Zighelboim, Israel
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David G.
    Wright, Jason D.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 535 - 540
  • [6] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu, Anca
    Levenback, Charles F.
    Slomovitz, Brian M.
    Bodurka, Diane C.
    Gershenson, David Marc
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] PHASE I/II STUDY OF CARBOPLATIN AND PRALATREXATE IN PATIENTS WITH RECURRENT PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
    del Carmen, M.
    Campos, S.
    Krasner, C.
    Berlin, S.
    Supko, J.
    Atkinson, T.
    Birrer, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 419 - 420
  • [8] Multicenter observational study on optimal regimen of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, and peritoneal cancer
    Shibutani, Takashi
    Nagao, Shoji
    Sato, Shinya
    Takehara, Kazuhiro
    Matsuoka, Hirofumi
    Sueoka, Kotaro
    Tomono, Katsuyuki
    Usami, Tomoka
    Sakashita, Tomohisa
    Ujihara, Yusuke
    Nagaji, Makoto
    Nakamura, Hiroko
    Tanaka, Tamaki
    Kigawa, Junzo
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S170 - S170
  • [9] Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Sabbatini, P
    Aghajanian, C
    Dizon, D
    Anderson, S
    Dupont, J
    Brown, JV
    Peters, WA
    Jacobs, A
    Mehdi, A
    Rivkin, S
    Eisenfeld, AJ
    Spriggs, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4523 - 4531
  • [10] Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Taylor, Sarah E.
    Chu, Tianjiao
    Edwards, Robert P.
    Zorn, Kristin Kelley
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345